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Introduction
Many kinds of tobacco product, such as cigars, pipes, and nasal or oral snuff, are used throughout the world, though the cigarette is the predominant form used today. The past few years has seen a rapid increase in the availability of novel tobacco and nicotine containing products, in particular electronic cigarettes, known as electronic vapor products (Walele et al., 2016; Marsot and Simon, 2016) , and heated tobacco products (Sakaguchi et al., 2014; Lüdicke et al., 2016; Haziza et al., 2016) . Among these new product forms, some have been aimed designed to reducing smokers' exposure to chemicals for which health concerns have been raised (Frost-Pineda et al., 2008) .
Nicotine is the major alkaloid in tobacco leaf and therefore present in tobacco products, and its pharmacokinetics has been studied extensively following cigarette smoking and the use of some other forms of tobacco product. The absorption rate of nicotine is slower with the use of oral moist snuff and chewing tobacco compared to smoking cigarettes, and this difference has been explained by the differences in the absorption site of nicotine: in the former cases, primary absorption site is the oral mucosa while in the latter it is the lungs (Benowitz et al., 1988; Foulds et al., 2003) . Additionally, the absorption rate of nicotine following the use of electronic cigarettes is delayed compared with conventional cigarettes (Marsot and Simon, 2016) . Given these previous findings, different forms of tobacco product may have different pharmacokinetic profiles due to the absorption site of nicotine.
The pharmacokinetics of nicotine demonstrated by various kinds of tobacco product has provided valuable information to clarify the extent to which individuals are exposed to nicotine when these tobacco products are used. Since nicotine intake delivered from tobacco products varies among smokers due to differences in their puffing behavior, accurate estimation of the intake of nicotine would contribute to a more precise evaluation of its pharmacokinetics. Methods for estimating the amount of nicotine delivered from conventional cigarettes during smoking (mouth level exposure [MLE]) have been thoroughly described (Watson et al., 2004; Shepperd et al., 2006 Shepperd et al., , 2009 . However, few methods have been reported for estimating the intake of nicotine from tobacco products other than cigarettes.
The objective of the present study was to investigate the pharmacokinetics of nicotine when using a prototype novel tobacco vapor (PNTV) product in comparison with smoking a conventional cigarette. The pharmacokinetic parameters were calculated from the blood nicotine concentrations and the estimated MLE of nicotine following controlled product use. In this study, the MLE of nicotine from PNTV product use was estimated in a different way than the MLE of nicotine from cigarette smoking.
Material and methods

Study design
This study was employed an open-label, two-sequence, twoperiod, randomized crossover design to investigate the pharmacokinetics of nicotine following the use of a PNTV product in comparison with smoking a commercially available conventional cigarette (CC1: 1 mg tar and 0.1 mg nicotine values, measured by ISO machine-smoking (ISO 3308, 2000) and printed on the package). The study was conducted at a single center in Japan. The study was approved by the Institutional Review Board of Japan Tobacco Inc. and the medical institution, conducted in accordance with Good Clinical Practice and the Declaration of Helsinki, and registered at the UMIN Clinical Trials Registry (UMIN000017297). All participants provided written informed consent to participate in the study.
Subjects
Healthy Japanese adult male smokers aged 21e65 years were eligible to participate if they smoked an average of 11 or more manufactured cigarettes per day at screening and had smoked for at least 12 months before entering the trial. Before entering the trial, the health conditions of subjects were confirmed by physical examination, medical history, vital signs, electrocardiogram, and clinical laboratory tests. Subjects were excluded if they had a body mass index (BMI) of less than 18.5 or of 25.0 kg/m 2 or more; a urinary cotinine level less than 200 ng/mL at screening, as determined using an immunoassay kit (One Step Cotinine Test Device, Accuracy-One Inc., California, USA); or had used any prescription smoking cessation treatment within the 4 week period before entering the study. The target sample size was determined as 20 subjects according to the guidelines on the investigation of bioequivalence (MHLW, 2012) , and 24 subjects were subsequently enrolled.
Procedure
On Day 1, Subjects checked in to the clinic and abstained from their regular tobacco product use. Days 2 and 3 were product use days. On each product use day, subjects used a PNTV product or smoked one CC1 under controlled use according to the randomization schedule. The controlled use of both PNTV product and CC1 consisted of 10 puffs for 3 min at approximately 20-s intervals. On Day 4, subjects were discharged following completion of health assessments.
Test tobacco product
The PNTV product consisted of a power supply unit, a cartridge with a heater and liquid, and a capsule filled with tobacco blend (Fig. 1) . The PNTV product generates a nicotine-free vapor via electrical heating of a liquid, which contains glycerin, propylene glycol and water and does not contain nicotine and flavor unlike major e-liquids for electronic cigarettes. The vapor then passes through the tobacco capsule. In doing so, evaporated constituents arising from the tobacco blend, including nicotine and flavors, pass into the vapor, which can then be inhaled by the user. The nicotine yield of the PNTV product in 50 puffs, which is the intended puff number of one capsule, was 1.10 mg per capsule as measured by the Health Canada machine-smoking test regimen (puff volume: 55 mL, puff duration: 2 s, and puff frequency: 2/min) (Health Canada, 1999) . In addition, we selected a CC1 as a comparator of PNTV product in this study, in order to approximate the estimated amount of nicotine delivered under the controlled use condition between investigational tobacco products from the above mentioned results of chemical analysis.
Measures
Baseline characteristics
The baseline characteristics of subjects, included gender, age, BMI, daily cigarette consumption, smoking history, and the ISO tar yield of the subject's usual cigarette brand, were recorded at screening. The trans-3'-hydroxycotinine:cotinine ratio, which is reported as an indicator of CYP2A6 activity (Mooney et al., 2008; Swan et al., 2009; Dempsey et al., 2004) , was calculated by the plasma concentration of trans-3'-hydroxycotinine and cotinine on Day 2. Plasma concentrations of trans-3'-hydroxycotinine and cotinine were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using validated analytical methods with appropriate quality controls at LSI Medience Corporation (Tokyo, Japan). The limits of quantification for trans-3'-hydroxycotinine and cotinine were 0.500 ng/mL.
Estimation of mouth levels of nicotine exposure
The MLE of nicotine from CC1 smoking was estimated by using cigarette part-filter analysis, which is a method commonly used to estimate cigarette smoke constituent yield to smokers (Shepperd et al., 2009 ). Puff volume, puff duration, puff interval, and butt length were set as parameters for preparing a calibration curve, and machine smoking of CC1 was then conducted using combinations of these parameters (18 conditions in total), followed by analysis of the amount of residual nicotine contained in the 10 mm mouth-end section of the filter and the amount of nicotine delivered in the mainstream smoke. CC1 has the dual-filter consist from acetate filter and charcoal filter, and the mouth-end section of the 10 mm acetate filter from CC1 smoked by subjects were pulled out by tweezers. The filter then placed in glass jars by clinical staff immediately after smoking and sent to Japan Tobacco Inc. (Tokyo, Japan) for analysis. Each spent filter underwent an extraction process using 2.0 mL of methanol containing 10% acetic acid, and the amounts of nicotine contained in the extracts were measured by gas chromatography (7890, Agilent Technologies, California, USA) using a flame ionization detector. The MLE of nicotine during CC1 smoking was subsequently calculated from the calibration curve ( Fig. 2(A) ).
Since the PNTV product does not contain a filter to filtrate the chemical components in the vapor, the part-filter analysis method could not be used for it. In this study, the estimated MLE of nicotine during PNTV product use was calculated from the puffing topography data (puff volume and puff duration) recorded using the CReSSmicro device (Plowshare Technologies, Inc./Borgwaldt KC, Inc., Richmond, USA). Machine aspiration was performed under 15 conditions that consisted of combinations of the puff volume (ranging from 25 to 140 mL) and the puff duration (ranging from 1.5 to 2.5 s) during 10 puffs at 20-s intervals. This was followed by analysis of the amount of nicotine delivered in the vapor (Fig. 2(B) ). Multiple regression analysis was conducted by using the amount of delivered nicotine in the vapor as an objective variable and the aspiration parameters as explanatory variables, and the estimate formula was selected the best relational expression from the result of multiple regression analysis. The MLE of nicotine during PNTV product use was estimated using the following equation:
, where Y was the estimated MLE of nicotine (mg), TPV was the total puff volume (mL), PD was the puff duration (msec), and the coefficient of determination was 0.977.
Pharmacokinetics
Blood samples (2 mL) for plasma nicotine analysis were collected via an intravenous catheter inserted into the cutaneous vein of the forearm. Blood was collected at approximately 5 min prior to and at 2, 3, 4, 5, 10, 15, 20, 25, 30, 45, 60, 90 , and 120 min after the start of product use on Days 2 or 3. Three additional blood samples were collected following the use of PNTV product (at 6, 7, and 8 min following the start of PNTV product use), with consideration given to a delayed peak concentration of nicotine. Plasma nicotine was analyzed by LC-MS/MS using validated analytical methods with appropriate quality controls at LSI Medience Corporation (Tokyo, Japan). The limit of quantification for nicotine was 0.500 ng/mL.
The pharmacokinetic parameters of the maximum observed plasma concentration (C max ), the time to reach C max (t max ), the terminal elimination half-life (t 1/2 ), and the area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration (AUC last ) were determined from the nicotine concentrations following product use. The pharmacokinetic parameters were calculated from t ¼ 0 min (time of first puff of PNTV product or CC1) on Day 2 or 3. For calculation of the pharmacokinetic parameters, concentration values below the lower limit of quantification were set to 0 before the first quantifiable concentration and set to 50% (0.250 ng/mL) of the lower limit of quantitation thereafter. When plasma nicotine concentrations higher than the lower limit of quantification (0.500 ng/mL) were observed prior to product use, pharmacokinetic parameters were calculated using concentrations adjusted to those obtained just prior to product use and the elimination rate constant (kel) of each subject. The concentrations were adjusted using the following equation:
, where C t(adj) was the adjusted concentration, C t was the observed concentration, C 0 was the concentration prior to product use, and t was time. In addition, the relative bioavailability of PNTV product compared with CC1 was determined from the fraction of AUC last of PNTV product to that of CC1, adjusted for each MLE.
All non-compartmental pharmacokinetic parameters were calculated from the adjusted plasma nicotine concentrations and actual sample times using WinNonlin (version 6.2.1, Pharsight Corporation, California, USA) or SAS (version 9.3, SAS Institute Inc., North Carolina, USA). The AUC last was calculated using the linearup/log-down trapezoidal method.
Safety
Monitoring for any adverse events (AEs) was conducted by checking vital signs, clinical laboratory values and physical examinations.
Statistical analysis
Only data from completed subjects who completed the study and who did not deviate from the protocol were included in the statistical analysis.
The C max , t 1/2 , and AUC last were compared between the two products using a mixed model that included investigational tobacco product, period, and sequence as fixed effects and subjectwithin-sequence as a random effect. C max , t 1/2 , and AUC last were log-transformed for the statistical analysis, and adjusted geometric least square (LS) mean ratios (PNTV product vs. CC1) and 95% confidential intervals (CIs) were calculated. The MLE and t max were compared between the two products using a mixed model that included investigational tobacco product, period, and sequence as fixed effects and subject-within-sequence as a random effect. And, LS mean differences (PNTV product vs. CC1) were calculated for MLE and t max .
Results
Study population
Twenty-four subjects were enrolled in the study, and all subjects completed the study. No major protocol deviations were reported. Subjects had a mean age of 39.0 years (range: 21e63 years) and a mean BMI of 21.1 kg/m 2 (range: 18.5e24.9 kg/m 2 ). Subjects smoked their usual brand of cigarettes with a mean tar value of 8.8 mg (range: 1e18 mg) and a mean daily cigarette consumption of 18.1 cigarettes (range: 12e30 cigarettes), and a mean smoking history of 18.9 years (range: 1e43 years). The average trans-3'-hydroxycotinine:cotinine ratio was 0.216 (range: 0.018e0.591).
Pharmacokinetics of nicotine
The mean plasma nicotine concentration profiles of PNTV product and CC1 are shown in Fig. 3 . The profiles illustrate the differences between the investigational tobacco products.
The MLE and pharmacokinetics parameters of nicotine are given in Table 1 . The MLE of nicotine from the use of a PNTV product or a CC1 were 0.355 and 0.540 mg, respectively. This result showed that the MLE of nicotine for PNTV product was significantly lower than that for CC1, with an LS mean difference of 0.202 (95% CI: 0.120, 0.284) mg. The C max and AUC last values for PNTV product were 5.39 (95% CI: 4.34, 6.69) ng/mL and 4.12 (95% CI: 3.43, 4.95) ng,h/mL, respectively, and those for CC1 were 11.8 (95% CI: 9.49, 14.6) ng/mL and 6.03 (95% CI: 5.02, 7.25) ng,h/mL, respectively. The results showed that the C max and AUC last for PNTV product were significantly lower than those for CC1, with LS mean ratios of 45.7 (95% CI: 34.1, 61.4)% and 68.3 (95% CI: 54.3, 85.9)%, respectively. The t max for both PNTV product and CC1 were 3.83 min. No significant difference in t max was observed between PNTV product and CC1, with an LS mean difference of À0.542 (95% CI: À1.11, 0.03) min. The t 1/2 for PNTV product and CC1 was 1.86 (95% CI: 1.58, 2.19) h and 1.66 (95% CI: 1.41, 1.95) h, respectively, and no significant difference in t 1/2 was observed between PNTV product and CC1 with an LS mean ratio of 89.1 (95% CI: 78.2, 102) %. Additionally, the relative bioavailability of PNTV product to CC1 was 104%.
Safety
One subject experienced an AE (vasovagal reaction) after PNTV product use, and no AE was reported after CC1 smoking. There were no serious AEs reported during the entire study. 
Table 1
Pharmacokinetics of nicotine following use of a prototype novel tobacco vapor (PNTV) product or smoking of a conventional cigarette (CC1). 
Discussion
The PNTV product differs from most existing "heated tobacco" products in that the tobacco is not directly heated during use. PNTV product also differs from many e-cigarettes in that the liquid being vaporized does not contain nicotine. In this study, the pharmacokinetics of nicotine between this novel tobacco product and conventional cigarette smoking were compared.
The C max and AUC last following the use of PNTV product was 45.7% and 68.3% of that obtained with CC1, respectively. The estimated nicotine MLE following the use of PNTV product was approximately two-thirds that obtained following the smoking of CC1, and the differences in C max and AUC last between PNTV product and CC1 might therefore be explained by differences in nicotine intake. The relative bioavailability of PNTV product to CC1 was approximately 104%, as demonstrated by the fraction of AUC last of PNTV product to CC1 adjusted for each MLE, which suggests that the bioavailability of nicotine for PNTV product is not markedly different from that for cigarettes.
The t max of plasma nicotine indicated the same values (approximately 3.83 min) between PNTV product use and CC1 smoking under the conditions of this study. Some previous reports have indicated that tobacco and nicotine containing products took longer to reach t max compared to cigarette and suggested the nicotine delivered from the products might be absorbed via other sites, e.g. oral mucosa and pharynx, compared to conventional cigarettes (Russell et al., 1976 (Russell et al., , 1987 Sobue et al., 2006; Digard et al., 2013; Lunell et al., 2000; Miura et al., 2013; Walele et al., 2016; Farsalinos et al., 2015) . On the other hand, there was no significant difference in the t max of plasma nicotine between PNTV product use and CC1 smoking in this study. Thus, our results suggest that the PNTV product delivers nicotine via similar absorption sites as cigarettes rather than other previous reported tobacco and nicotine containing products. However, in order to identify the absorption sites and the relationship between absorption sites and absorption rate of delivered nicotine from the tobacco products strictly, further investigation, such as a study using isotope-labeled nicotine that allows direct measurement of nicotine intake (Bergstr€ om et al., 1995) , is necessary.
There was no significant difference in the t 1/2 of plasma nicotine between PNTV product use (approximately 1.66 h) and CC1 smoking (approximately 1.86 h) under the conditions of this study, despite the differences observed in other pharmacokinetic parameters and the MLE of nicotine. The t 1/2 of plasma nicotine following the use of PNTV product was consistent with previously reported values obtained following cigarette smoking (Hukkanen et al., 2005; Yun et al., 2008; Yuki et al., 2013) , which suggests that the elimination rate of nicotine for PNTV product is not markedly different from that for cigarettes.
Additionally, there was a probability that some smokers with a lower nicotine metabolic capacity were enrolled in this study because nine subjects had a lower trans-3'-hydroxycotinine:cotinine ratio than the reported ratio for smokers with decreased activity alleles of CYP2A6 (Swan et al., 2009 ). Even though this study was designed as crossover trial to avoid influencing the results in pharmacokinetic parameters from nicotine metabolic activity in each subject, we supplementary conducted sub-grouping analysis related to subjects' nicotine metabolic activities. As the result of sub-grouping analysis based on the reported mean of ratio of lower activity metabolizers (0.16 in Swan et al., 2009 ), the t 1/2 for PNTV product and CC1 was slightly longer in smokers with lower metabolic activity (1.91 ± 0.608 and 2.51 ± 1.27 h, respectively) than in smokers with normal metabolic activity (1.70 ± 0.729 and 1.73 ± 0.559 h, respectively). Also, the other obtained pharmacokinetics parameters did not show any notable differences between the sub-groups, and our findings suggest that these pharmacokinetics parameters, other than t 1/2 , were not affected from the nicotine metabolic activity in this study.
In summary, under the conditions of the present study, the pharmacokinetics of nicotine following PNTV product use were not markedly different from those following cigarette use, while the PNTV product provided less nicotine following a controlled single use. Limitations of the study are that the using duration and puff number were fixed to acquire clearer pharmacokinetic profiles by controlling the time of dose, and the subjects could use the PNTV product only once during the study period. Furthermore, smokers have been reported to change their behavior for adaptation to new tobacco products by taking time under 'real world' (Scherer, 1999; Trtchounian et al., 2010; Farsalinos et al., 2015) . In order to assess the amount of nicotine that the PNTV product provides under 'real world' conditions, it would be beneficial to carry out a further longterm study that allows subjects to adapt their behavior to PNTV product use.
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